AMNC yields 166666.67% · ABBV yields 3.06%● Live data
📍 AMNC pulled ahead of the other in Year 1
Combined, AMNC + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AMNC + ABBV for your $10,000?
Amincor, Inc., through its subsidiaries, manufactures and sells bakery food products. It provides various sliced bread, yeast and cake doughnuts, frozen donuts, cookies, and snack products to supermarket "in-store" bakery departments, and food service channels. It also offers water remediation services, such as water testing and evaluation, system engineering and design, system training servicing, and maintenance service in the northeast United States, as well as is involved in treating and discharging petroleum impacted water into the sanitary sewer system. The company serves oil companies, petroleum marketers, jobbers, municipal entities, school districts, industrial facilities, and other businesses. In addition, it provides maintenance, repair, and construction services to customers with underground petroleum storage tanks and petroleum product dispensing equipment, as well as is engaged in environmental consulting, site assessment, analysis, and management of site remediation for owners and operators of petroleum storage facilities. The company serves national and multinational enterprises, as well as to local and national governmental agencies and municipalities. The company was formerly known as Joning Corp and changed its name to Amincor, Inc. in February 2010. Amincor, Inc. was incorporated in 1997 and is headquartered in New York, New York.
Full AMNC Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.